APOE and early-onset autosomal dominant Alzheimer disease: Interestingly, even healthy Apolipoprotein E (APOE4) carriers, the strongest marker of genetic susceptibility of developing Alzheimer's disease, demonstrate impairments in interpreting auditory targets [9]. Donepezil aims to increase ACh to make up for the disruptions of cholinergic neurons and increase acetylcholinesterase inhibition to improve cognitive processing efficiency [10].